Novartis AG
Compare this stock
NVS Stock Report Card
$
56%
Performance
Score:
100/100
NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
Score:
67/100
3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.
Technicals
Score:
10/100
NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
Score:
39/100
NVS has missed earnings 5 times in the last 20 quarters.
Profit
Score:
73/100
Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.
Volatility
Score:
44/100
NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
Novartis AG Summary
New York Stock Exchange / NVS
Healthcare
Drug Manufacturers - General
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
NVS scored highly on our reportcard. Here are some similar companies and how they performed.
